BNT162b2 Vaccine Effectiveness in Preventing Asymptomatic Infection With SARS-CoV-2 Virus: A Nationwide Historical Cohort Study

Article Medicine, General & Internal

SARS-CoV-2 Transmission From People Without COVID-19 Symptoms

Michael A. Johansson et al.

Summary: The study suggests that more than half of COVID-19 transmission may come from asymptomatic individuals, highlighting the importance of measures beyond identifying and isolating symptomatic cases in controlling the spread of the virus.

JAMA NETWORK OPEN (2021)

Add to Collection

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Jocelyn Keehner et al.

Summary: A study showed that while 71% of healthcare workers tested positive for SARS-CoV-2 within 2 weeks after receiving the vaccine, the percentage decreased after the second dose.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Medicine, General & Internal

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

Gabriel Chodick et al.

Summary: The short-term effectiveness of the first dose of the BNT162b2 vaccine against SARS-CoV-2 infection 13 to 24 days after immunization in a real-world setting was assessed, showing comparable results to the phase III randomized clinical trial.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Immunology

Postvaccination COVID-19 among Healthcare Workers, Israel

Sharon Amit et al.

Summary: Symptoms of COVID-19 can be mistaken for vaccine-related side effects, highlighting the importance of promptly testing for COVID-19 after vaccination. In a study of healthcare workers in Israel, a small percentage developed COVID-19 within 10 days of vaccination, emphasizing the need for vigilance in monitoring post-vaccination symptoms.

EMERGING INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology